MAIN STAGE | New Trends in China's Pharmaceutical R&D
SESSION 1:
Global Trends in Pharmaceutical Innovation
SESSION 2:
Technology and Capital Driving Pharmaceutical Innovation
SESSION 3:
Global Market Access and Compliance Strategies
STAGE D | Small Molecule Drug
SESSION 1:
New Targets, New Breakthroughs
SESSION 2:
Tackling Undruggable Targets
SESSION 3:
Clinical Development Strategies for Small Molecule Drugs
SESSION 4:
Innovations and Future Trends in Small Molecule Drug Applications
DAY1 STAGE E | Antibody Drug and ADC
SESSION 1:
Cutting-Edge Advances in Bispecific and Multispecific Antibodies
SESSION 2:
Differentiated Development of ADC Drugs
DAY1 STAGE F | Early Drug Development and Translational Medicine Forum
SESSION 1:
Target Discovery and Lead Compound Screening
SESSION 2:
Innovative Drug Discovery: From Design to Validation
SESSION 3:
Early Drug Development: Translational Challenges and Opportunities
DAY1 STAGE G | Clinical Trial Operations and Innovations
SESSION 1:
Digital and Decentralized Clinical Trials
SESSION 2:
Managing Global Multi-Center Clinical Trials
SESSION 3:
Data Management and Compliance in Clinical Trials
SESSION 4:
Patient-Centric Innovations in Clinical Trial
DAY2 STAGE A | Pharma BD and Business Collaboration
SESSION 1:
Pharma Collaboration and BD Transaction Strategies
SESSION 2:
Domestic Roadshows
SESSION 3:
International Roadshows
DAY2 STAGE B | Global Market Access and Cross-border Pharma Collaboration
SESSION 1:
Launching Innovative Drugs Globally
SESSION 2:
Cross-border Collaborations for Pharma R&D
SESSION 3:
Navigating Regulatory Challenges for Global Market Access
DAY2 STAGE C | AI,Data: Ushering in the Smart Era of Drug Discovery
SESSION 1:
AI-Driven Target Identification
SESSION 2:
Data Science in Drug Design and Optimization
SESSION 3:
Integration of AI in Drug Development Workflow
SESSION 4:
Smart Clinical Trials and Data Analytics
DAY2 STAGE D | Nucleic Acid and mRNA Drug
SESSION 1:
Breakthroughs in Nucleic Acid Therapies
SESSION 2:
Delivery Technologies and Innovations for Nucleic Acid Drugs
SESSION 3:
mRNA Vaccine and Drug Development Progress and Future Applications mRNA
DAY 2 AM STAGE E | Immuno-Oncology Drug
SESSION 1:
Advances in Cancer Immunotherapy
SESSION 2:
Personalized Cancer Immunotherapy and Novel Targets
DAY2 STAGE F | Cell and Gene Therapy
SESSION 1:
Breakthroughs in Cell Therapy
SESSION 2:
Gene Editing and Therapy Innovations
SESSION 3:
Emerging Therapies in CGT
SESSION 4:
CGT Drug CMC Process Development CGT
DAY 2 AM STAGE G | Peptide Drug
SESSION 1:
Innovations in Peptide Synthesis and Design
SESSION 2:
Peptide-Based Innovative Drugs and Immuno-Oncology
DAY2 PM STAGE G | Radiopharmaceutical
SESSION 1:
Advancements in Radiopharmaceutical Technology
SESSION 2:
Regulatory and Clinical Challenges in Radiopharmaceuticals
